Founded in 2008, Adarza BioSystems, Inc. has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today.

Adarza is a leading developer and manufacturer of label-free biosensor assays and instruments servicing life science research, drug development and, in-vitro diagnostics customers.

Adarza offers a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.

Adarza’s platform is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing.

Adarza’s technology offers key performance benefits in speed, ease of use, large screening arrays, and custom assays as well as industry-standard expectations for sensitivity, sample size, and dynamic range.

Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology, and infectious diseases research.

For more information, visit Adarza Biosystems or follow their updates on:



  • $64.1m
  • 29

Adarza Biosystems Articles

Adarza BioSystems Raises Another $25 Million to Launch Platform for Research and Drug Development

Dollar sign fundraising

12 Fundraising Tips for BioTech Companies from Cultivation Capital’s Life Sciences Fund

As Adarza Scales Up, St. Louis Hopes for an Important Win

Adarza BioSystems

Adarza BioSystems Closes on $17 Million – What’s Next for the Life Science Startup

Adarza BioSystems Raises $5 Million in Series B Investment Round

That’s Life (Sciences)

Meet Arch Grants: STL’s Own Innovative Funding Resource

From NY To STL: Why This Life-Science Company Relocated To The Midwest